Ohtuvayre (Ensifentrine)-What is the Chinese name of Ensifentrine?

Ohtuvayre (Ensifentrine)-Ensifentrine is a new type of drug mainly used to treat chronic obstructive pulmonary disease (COPD). Its Chinese transliteration name is "Ensifentrine". The unique feature of this drug is that it is a dual-action drug that has a bronchodilatory effect and suppresses the inflammatory response, thereby improving the patient's respiratory function.

Chronic obstructive pulmonary disease is a chronic disease characterized by airflow limitation and persistent dyspnea, often caused by long-term smoking or environmental pollution. COPD patients usually experience symptoms such as cough, phlegm, and shortness of breath. In severe cases, it may even affect daily life and work. Traditionally, the treatment of COPD usually includes the combination of bronchodilators and anti-inflammatory drugs, and exefentine as an emerging treatment option provides new hope for these patients through its unique mechanism.

Ensefentin inhibits specific phosphodiesterases (PDE3 and PDE4), causing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) to increase, thereby promoting bronchial dilation and reducing inflammatory responses in the airways. This dual mechanism of action allows ensefentin to show good efficacy in improving lung function, especially in patients who have not responded well to other treatments.

The drug is usually inhaled through a nebulizer, which can quickly reach the respiratory tract and achieve rapid effect. At the same time, due to the convenience of its pharmaceutical form, it makes it easier for patients to follow the treatment plan in daily management, thus improving treatment compliance.

In general, the emergence of exefantine provides a new treatment method for COPD patients that may improve their quality of life. In clinical trials, the drug has shown good safety and tolerability, but the specific effects vary depending on individual differences, so patients should consult their doctor before use to ensure that it is suitable for their treatment plan.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6433c98-41a0-4f99-8f7f-d0e9db6e3f40